🇺🇸 FDA
Patent

US 11866727

Materials and methods for treatment of glycogen storage disease type 1A

granted A61KA61K38/00

Quick answer

US patent 11866727 (Materials and methods for treatment of glycogen storage disease type 1A) held by CRISPR THERAPEUTICS AG expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/00